ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1704

Consistent Safety and Tolerability of Secukinumab over Long-Term Exposure in Patients with Active Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis: Updated Pooled Safety Analyses

Philip J Mease1, Iain B McInnes2, Kristian Reich3, Mats Andersson4, Aiyang Tao5, Todd Fox4 and Chetan Karyekar5, 1Swedish Medical Center and University of Washington, Seattle, WA, 2University of Glasgow, Glasgow, Great Britain, 3Dermatologikum Hamburg and Georg-August-University Göttingen, Hamburg, Germany, 4Novartis Pharma AG, Basel, Switzerland, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: clinical trials, psoriasis, Psoriatic arthritis and safety

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Pooled safety data from the psoriasis (PsO) and psoriatic arthritis (PsA) clinical trial programs of secukinumab (SEC), through approximately 1 year, have been reported previously.1,2 Specifically, the exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) and serious adverse events (SAEs) for PsO and PsA were 252.9 and 7.8, and 210.3 and 9.0 per 100 patient (pt)-years, respectively. Here we present updated analyses following additional exposure (with a 25 Dec 2015 data cut-off), either from a larger study pool (PsO) and/or an extended follow-up period (PsO, PsA).  

Methods: The updated PsO pool consisted of 4 Phase II and 9 Phase III studies in pts with moderate-to-severe plaque PsO, including 2 active comparator studies with etanercept (ETN) and ustekinumab (UST), respectively; the PsA pool consisted of 2 PBO-controlled Phase III studies in pts with active PsA. SEC doses differed in the studies and included intravenous (3–10 mg/kg) or subcutaneous (75–300 mg) loading, followed by subcutaneous maintenance dosing (300, 150, or 75 mg). PBO pts were re-randomized to SEC between 12–24 weeks in the various studies. EAIRs were calculated to minimize the impact of between-group differences in treatment exposure.

Results: In both the PsO and PsA pools, the most frequently reported AEs with SEC were non-serious infections, including nasopharyngitis and upper respiratory tract infection, headache, and arthralgia (Table). The EAIRs of AEs of special interest, including Crohn’s disease, Candida infections, serious infections, neutropenia, major adverse cardiac events, and malignancy, with SEC (reported in the Table) were similar across PsO and PsA studies, and comparable to those reported previously.1,2

Conclusion: Treatment with SEC was well tolerated in PsO and PsA patients. This longer-term safety assessment was consistent with previous reports,1,2 and did not identify any new safety signals. The long-term safety profile of SEC was comparable across PsO and PsA patients, allowing a broader understanding of the safety of SEC in these two closely related disease populations. References: 1. Van de Kerkhof PCM, et al. J Am Acad Dermatol 2016;75:83–98; 2. Mease PJ, et al. Arthritis Rheumatol 2015; 67 (suppl 10):A2886


Disclosure: P. J. Mease, AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Lilly, Novartis, Pfizer, Sun, UCB, 2,AbbVie, Amgen, Bristol Myers Squibb, Celgene, Crescendo, Corrona, Demira, Janssen, Lilly, Merck, Novartis, Pfizer, Sun, UCB, Zynerba, 5,AbbVie, Amgen, Bristol Myers Squibb, Celgene, Crescendo, Genentech, Janssen, Novartis, Pfizer, UCB, 8; I. B. McInnes, Novartis, Eli Lilly, Pfizer, AbbVie, Roche, Janssen, 2,Novartis, Eli Lilly, Pfizer, AbbVie, Roche, Janssen, 5; K. Reich, AbbVie, Amgen, Biogen, Boehringer Ingelheim Pharma, Celgene, Centocor, Covagen, Forward Pharma, GlaxoSmithKline, Janssen-Cliag, Leo, Lilly, Medac, Merck Sharp and Dohme Corp., Novartis, Ocean Pharma, Pfizer, Regeneron, Takeda, UCB Pharma, Xenoport, 2,AbbVie, Amgen, Biogen, Boehringer Ingelheim Pharma, Celgene, Centocor, Covagen, Forward Pharma, GlaxoSmithKline, Janssen-Cliag, Leo, Lilly, Medac, Merck Sharp and Dohme Corp., Novartis, Ocean Pharma, Pfizer, Regeneron, Takeda, UCB Pharma, Xenoport, 5; M. Andersson, Novartis, 3; A. Tao, Novartis, 3; T. Fox, Novartis Pharma AG - Switzerland, 1,Novartis Pharma AG - Switzerland, 3; C. Karyekar, Novartis Pharmaceuticals, 1,Novartis Pharmaceuticals, 3.

To cite this abstract in AMA style:

Mease PJ, McInnes IB, Reich K, Andersson M, Tao A, Fox T, Karyekar C. Consistent Safety and Tolerability of Secukinumab over Long-Term Exposure in Patients with Active Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis: Updated Pooled Safety Analyses [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/consistent-safety-and-tolerability-of-secukinumab-over-long-term-exposure-in-patients-with-active-psoriatic-arthritis-and-moderate-to-severe-plaque-psoriasis-updated-pooled-safety-analyses/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/consistent-safety-and-tolerability-of-secukinumab-over-long-term-exposure-in-patients-with-active-psoriatic-arthritis-and-moderate-to-severe-plaque-psoriasis-updated-pooled-safety-analyses/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology